Drug intelligence / Profile preview

GKIND001A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GKIND001A is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development by China Resources Guokang Pharmaceutical. It is primarily being investigated for the treatment of gastrointestinal (GI) tumors and other anti-tumor applications. As of the latest pipeline information, the drug is in the IND-enabling (Pre-IND) phase. By targeting BTK, GKIND001A aims to inhibit the signaling pathways that contribute to the growth and survival of malignant cells in the digestive tract.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on GKIND001A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND001A.

Explore the full profile